Traders should monitor upcoming IND filing for CGT1263 and further clinical updates on CGT4255 combinations. Despite recent insider selling of $242.6M, the data readout supports long-term pipeline optionality and could attract partnership interest, especially in the competitive KRAS and HER2+ brain mets spaces.
Price Chart
Executive Summary
Cogent Biosciences presented preclinical data at AACR 2026 for two pipeline candidates: CGT1263, a pan-KRAS(ON) inhibitor with potential differentiation in skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor showing synergy with HER2 ADCs in resistant patients. IND submission for CGT1263 is expected later this year, while Phase 1 trials for CGT4255 are ongoing.
Key Facts
- Presented preclinical data for CGT1263, a pan-KRAS(ON) inhibitor with >500x selectivity for mutant KRAS over HRAS/NRAS, potentially reducing skin toxicity seen with multi-RAS inhibitors.
- CGT1263 shows sustained pERK inhibition and robust antitumor activity in preclinical models, with limited skin suppression suggesting a wider therapeutic window.
- Presented data for CGT4255, a brain-penetrant ErbB2 inhibitor with >100-fold selectivity over EGFR, active against key HER2 mutations and showing synergistic effects when combined with HER2 ADCs like T-DXd.
- IND submission for CGT1263 expected later in 2026; Phase 1 trial for CGT4255 is already ongoing.
- Management highlighted potential for 'multiple blockbuster programs' in the pipeline.
Financial Impact
Preclinical data enhances pipeline value; no immediate revenue impact but increases probability of clinical success and future monetization.
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- High valuation ($5.9B market cap) is sensitive to clinical setbacks or dilution risk.
- Recent insider selling raises concerns about near-term sentiment despite positive data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276106 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.02 (−25.31%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.02 (−6.28%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.02 (−10.89%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.02 (−12.32%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.02 (−16.12%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.02 (−16.72%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.02 (−11.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access